Immune checkpoint blockade (ICB) therapy has transformed cancer treatment; however, its therapeutic efficacy remains limited, largely due to insufficient intratumoral accumulation of checkpoint-blocking antibodies (e.g., anti-PD-L1) and suboptimal immune activation....
Chen et al. (2026) studied this question.